Dicot Pharma AB

F:KN0 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$68.06 Million
€66.31 Million EUR
Market Cap Rank
#21467 Global
#2332 in Germany
Share Price
€0.03
Change (1 day)
+21.32%
52-Week Range
€0.02 - €0.03
All Time High
€0.03
Categories
Companies in Germany Drug Manufacturers - Specialty & Generic
About

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

Dicot Pharma AB (KN0) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of June 2025: -0.275x

Based on the latest financial reports, Dicot Pharma AB (KN0) has a cash flow conversion efficiency ratio of -0.275x as of June 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-29.20 Million) by net assets (€106.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Dicot Pharma AB - Cash Flow Conversion Efficiency Trend (2021–2024)

This chart illustrates how Dicot Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Dicot Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Dicot Pharma AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
365330
KQ:365330
 		-0.070x
Diamond Biotechnology Co., Ltd
TWO:6815
 		-0.034x
Jalles Machado S/A
SA:JALL3
 		0.096x
Mayfield Group Holdings Ltd
AU:MYG
 		0.339x
Frontier Energy Ltd
AU:FHE
 		-0.012x
CATES ELEKTRIK
IS:CATES
 		-0.034x
Gaia Inc
NASDAQ:GAIA
 		0.017x
Coffee Day Enterprises Limited
NSE:COFFEEDAY
 		0.025x

Annual Cash Flow Conversion Efficiency for Dicot Pharma AB (2021–2024)

The table below shows the annual cash flow conversion efficiency of Dicot Pharma AB from 2021 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €111.67 Million €-58.87 Million -0.527x +48.26%
2023-12-31 €44.39 Million €-45.23 Million -1.019x +81.63%
2022-12-31 €5.36 Million €-29.71 Million -5.546x -507.88%
2021-12-31 €28.35 Million €-25.87 Million -0.912x --